Listing of Claims:

Please rewrite claims 49, 59, 69 and 79 and cancel claims 50-53, 60-63, 70-73 and 80-83 as follows.

1-48. (Canceled)

49. (Currently Amended) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)- $1\alpha,25$ -dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D_3 having the structure

50-53. (Canceled)

- 54. (Previously Presented) The method of claim 49 wherein the compound is administered orally.
- 55. (Previously Presented) The method of claim 49 wherein the compound is administered parenterally.
- 56. (Previously Presented) The method of claim 49 wherein the compound is administered transdermally.
- 57. (Previously Presented) The method of claim 49 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D_3 .

Application No. 10/780,103 Amendment Dated January 5, 2005 Reply to Office Action of October 5, 2004

- 58. (Previously Presented) The method of claim 49 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃.
- from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃ having the structure

60-63. (Canceled)

- 64. (Previously Presented) The method of claim 59 wherein the compound is administered orally.
- 65. (Previously Presented) The method of claim 59 wherein the compound is administered parenterally.
- 66. (Previously Presented) The method of claim 59 wherein the compound is administered transdermally.
- 67. (Previously Presented) The method of claim 59 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃.

Application No. 10/780,103 Amendment Dated January 5, 2005 Reply to Office Action of October 5, 2004

- 68. (Previously Presented) The method of claim 59 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D_3 .
- 69. (Currently Amended) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)- $1\alpha,25$ -dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D_3 having the structure

70-73. (Canceled)

- 74. (Previously Presented) The method of claim 69 wherein the compound is administered orally.
- 75. (Previously Presented) The method of claim 69 wherein the compound is administered parenterally.
- 76. (Previously Presented) The method of claim 69 wherein the compound is administered transdermally.
- 77. (Previously Presented) The method of claim 69 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D_3 .
- 78. (Previously Presented) The method of claim 69 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D_3 .

Application No. 10/780,103 Amendment Dated January 5, 2005 Reply to Office Action of October 5, 2004

79. (Currently Amended) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene- 1α -hydroxy-2-methylene-24-dehydro-19-norvitamin D_3 having the structure

80-83. (Canceled)

- 84. (Previously Presented) The method of claim 79 wherein the compound is administered orally.
- 85. (Previously Presented) The method of claim 79 wherein the compound is administered parenterally.
- 86. (Previously Presented) The method of claim 79 wherein the compound is administered transdermally.
- 87. (Previously Presented) The method of claim 79 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of 20(S)-26,27-dimethylene- 1α -hydroxy-2-methylene-24-dehydro-19-norvitamin D_3 .
- 88. (Previously Presented) The method of claim 79 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of 20(S)-26,27-dimethyl- 1α -hydroxy-2-methylene-24-dehydro-19-norvitamin D_3 .